GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.46 USD | -3.55% |
|
-3.07% | -13.76% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
| Sales 2024 * | 19.66B 2.83B | Sales 2025 * | 23.51B 3.39B | Capitalization | 124B 17.89B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.11B 735M | Net income 2025 * | 6.76B 973M | EV / Sales 2024 * | 4.97 x |
| Net cash position 2024 * | 26.57B 3.83B | Net cash position 2025 * | 33.5B 4.82B | EV / Sales 2025 * | 3.86 x |
| P/E ratio 2024 * |
24.5
x | P/E ratio 2025 * |
18.8
x | Employees | 2,204 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | -3.55% | ||
| 1 week | -3.07% | ||
| Current month | -8.19% | ||
| 1 month | -8.41% | ||
| 3 months | -2.45% | ||
| 6 months | -5.47% | ||
| Current year | -13.76% |
1 week
27.43
29.21
1 month
27.4330.63
Current year
26.3232.88
1 year
26.3242.72
3 years
26.1949.07
5 years
16.2449.07
10 years
3.7049.07
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.28% | 1 M€ | 0.00% | - | |
| 1.99% | 0 M€ | 0.00% | - | |
| 1.68% | 0 M€ | 0.00% | - | |
| 1.47% | 9 M€ | -4.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 27.46 | -3.55% | 436,367 |
| 24-04-24 | 28.47 | -0.32% | 456,129 |
| 24-04-23 | 28.56 | -1.42% | 560,041 |
| 24-04-22 | 28.97 | +0.94% | 452,366 |
| 24-04-19 | 28.7 | +1.31% | 361,029 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
1,916
DKK
Average target price
2,418
DKK
Spread / Average Target
+26.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.26% | 22.02B | |
| -17.84% | 20.9B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B | |
| -26.18% | 8.08B |
- Stock Market
- Equities
- GMAB Stock
- GMAB Stock
